**About the Editors**

#### **Veysel Kayser**

Veysel Kayser is an Associate Professor at The University of Sydney (USyd). He completed his B.Sc. degree in Chemistry at Hacettepe University (Turkey) and his Ph.D. in Physical Chemistry from the University of Leeds (UK) in 2004. Subsequently, he undertook post-doctoral fellowships at the Max-Planck Institute of Biochemistry (Germany) and in the Department of Chemical Engineering at MIT (US), and then he worked at MIT for several years as a senior staff scientist. In mid-2013, he took up his current position at USyd. For periods, he was also the Associate Dean for Research and the HDR coordinator at the Faculty of Pharmacy and served in the Multidisciplinary Advisory Board of the Marie Bashir Institute for Infectious Diseases and Biosecurity at USyd (now Sydney Institute for Infectious Diseases).

His research interests are in biologics and vaccines (influenza, rabies, COVID-19 etc.), development of biosimilars and biobetters–mainly therapeutic monoclonal antibodies (mAbs), antibody-drug-conjugates, nanoparticle-antibody complexes, protein engineering, novel formulations of biologics and vaccines, and investigating the mechanisms of protein unfolding and aggregation.

He has obtained five patents, and several patent applications are pending, published over fifty peer-reviewed research publications, has given over 100 talks on biologics and vaccines, and also serves as an editor or member of the editorial board of various journals. He has consulted for and received research funding from industry. He has received numerous awards and fellowships.

#### **Amita Datta-Mannan**

Amita Datta-Mannan is a Research Fellow and Clinical Pharmacologist in the Department of Exploratory Medicine and Pharmacology at Eli Lilly and Company. She earned her Bachelor of Science at McMaster University, Ontario, Canada, in 1998 and her Ph.D. in Protein and Physical Chemistry from Brown University and Indiana University in 2003. Dr. Datta-Mannan has over 17 years of experience as a pharmaceutical scientist leading cross-functional drug discovery and development teams in various technical and corporate leadership roles. She is passionate about enabling the progression of novel therapeutics and medicines to improve the quality of life. Along these lines, Dr. Datta-Mannan has contributed to discovery and development of multiple medicinal modalities including monoclonal antibodies, bispecific antibodies, antibody drug conjugates, peptides and fusion proteins for autoimmunity, oncology, diabetes, migrane and musculoskeletal disorders. Dr. Datta-Mannan has key platform expertise in the area of mechanisms influencing the disposition, biodistribution and metabolism of biologics following parenteral and oral delivery. She also developed the first surrogate chemokine receptor structures to dissect the structure-function relationship of receptor-ligand interactions for developing therapies directed at autoimmune disorders. Dr. Datta-Mannan has contributed to multiple patents, published over 50 peer reviewed manuscripts and abstracts, including invited scientific reviews and pharmaceutical industry whitepaper guidance documents for biologics, presented/chaired over 30 invited oral presentations and serves on the editorial/review board of several journals.
